TY - JOUR
T1 - Challenges posed by COVID-19 in cancer patients
T2 - A narrative review
AU - Mohseni Afshar, Zeinab
AU - Hosseinzadeh, Rezvan
AU - Barary, Mohammad
AU - Ebrahimpour, Soheil
AU - Alijanpour, Amirmasoud
AU - Sayad, Babak
AU - Hosseinzadeh, Dariush
AU - Miri, Seyed Rouhollah
AU - Sio, Terence T.
AU - Sullman, Mark J.M.
AU - Carson-Chahhoud, Kristin
AU - Babazadeh, Arefeh
N1 - Publisher Copyright:
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2021
Y1 - 2021
N2 - A novel coronavirus, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the causative agent of coronavirus disease 2019 (COVID-19). In early 2020, the World Health Organization declared COVID-19 the sixth public health emergency of international concern. The COVID-19 pandemic has substantially affected many groups within the general population, but particularly those with extant clinical conditions, such as having or being treated for cancer. Cancer patients are at a higher risk of developing severe COVID-19 since the malignancy and chemotherapy may negatively affect the immune system, and their immunocompromised condition also increases the risk of infection. Substantial international efforts are currently underway to develop specific methods for diagnosing and treating COVID-19. However, cancer patients’ risk profiles, management, and outcomes are not well understood. Thus, the main objective of this review is to discuss the relevant evidence to understand the prognosis of COVID-19 infections in cancer patients more clearly, as well as helping to improve the clinical management of these patients.
AB - A novel coronavirus, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the causative agent of coronavirus disease 2019 (COVID-19). In early 2020, the World Health Organization declared COVID-19 the sixth public health emergency of international concern. The COVID-19 pandemic has substantially affected many groups within the general population, but particularly those with extant clinical conditions, such as having or being treated for cancer. Cancer patients are at a higher risk of developing severe COVID-19 since the malignancy and chemotherapy may negatively affect the immune system, and their immunocompromised condition also increases the risk of infection. Substantial international efforts are currently underway to develop specific methods for diagnosing and treating COVID-19. However, cancer patients’ risk profiles, management, and outcomes are not well understood. Thus, the main objective of this review is to discuss the relevant evidence to understand the prognosis of COVID-19 infections in cancer patients more clearly, as well as helping to improve the clinical management of these patients.
KW - cancer
KW - COVID-19
KW - immunodeficiency
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85121577217&partnerID=8YFLogxK
U2 - 10.1002/cam4.4519
DO - 10.1002/cam4.4519
M3 - Review article
AN - SCOPUS:85121577217
SN - 2045-7634
JO - Cancer Medicine
JF - Cancer Medicine
ER -
